Back
Marathon Oil 10K Form
Sell
40
MRO
Marathon Oil
Last Price:
28.53
Seasonality Move:
2.78%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-02 | 10Q | MRO/Marathon Oil Quarterly |
| 2024-02-22 | 10K | MRO/Marathon Oil Annual |
| 2023-11-02 | 10Q | MRO/Marathon Oil Quarterly |
| 2023-08-03 | 10Q | MRO/Marathon Oil Quarterly |
| 2023-05-04 | 10Q | MRO/Marathon Oil Quarterly |
| 2023-02-16 | 10K | MRO/Marathon Oil Annual |
Receive MRO News And Ratings
See the #1 stock for the next 7 days that we like better than MRO
MRO Financial Statistics
Sales & Book Value
| Annual Sales: | $6.41B |
|---|---|
| Cash Flow: | $751M |
| Price / Cash Flow: | 7.98 |
| Annual Sales: | $20.44 |
| Price / Book: | 1.4 |
Profitability
| EPS (TTM): | 2.33000 |
|---|---|
| Net Income (TTM): | $1.33B |
| Gross Margin: | $2.68B |
| Return on Equity: | 11.83% |
| Return on Assets: | 6.76% |
Marathon Oil Earnings Forecast
Key Marathon Oil Financial Ratios
- The Gross Profit Margin over the past 34 years for MRO is 41.81%.
- The Selling, General & Administrative Expenses for MRO have been equal to 4.64% of Gross Profit Margin.
- The Research & Development expenses have been 0.00% of Revenue.
- The Interest Expense is 22.07% of Operating Income.
- The Net Earning history of MRO is 24.25% of Total Revenues.
- Per Share Earnings over the last 34 years have been positive in 17 years.
Marathon Oil Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Industry: | Oil, Gas & Consumable Fuels |
| Sector: | Energy |
| Current Symbol: | MRO |
| CUSIP: | 565849 |
| Website: | marathonoil.com |
Debt
| Debt-to-Equity Ratio: | 0.42 |
|---|---|
| Current Ratio: | 0.69 |
| Quick Ratio: | 0.59 |
Price-to-Earnings
| Trailing P/E Ratio: | 11.15 |
|---|---|
| Forward P/E Ratio: | 11.76 |
MRO Technical Analysis vs Fundamental Analysis
Sell
40
Marathon Oil (MRO)
is a Sell
Is Marathon Oil a Buy or a Sell?
-
Marathon Oil stock is rated a Sell
The current Marathon Oil [MRO] share price is $28.55. The Score for MRO is 40, which is 20% below its historic median score of 50, and infers higher risk than normal.